Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience.
Next-Generation Sequencing
off-label
on-label
precision oncology
therapy
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
31 Jan 2022
31 Jan 2022
Historique:
received:
23
12
2021
revised:
14
01
2022
accepted:
18
01
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Major advances in sequencing technologies and targeted therapies have accelerated the incorporation of oncology into the era of precision medicine and "biomarker-driven" treatments. However, the impact of this approach on the everyday clinic has yet to be determined. Most precision oncology reports are based on developed countries and usually involve metastatic, hard-to-treat or incurable cancer patients. Moreover, in many cases race and ethnicity in these studies is commonly unreported and real-world evidence in this topic is scarce. Herein, we report data from a total of 202 Chilean advanced stage refractory cancer patients. Retrospectively, we collected patient data from NGS tests and IHC in order to determine the proportion of patients that would benefit from targeted treatments. Overall >20 tumor types were included in our cohort and 37% of patients (
Identifiants
pubmed: 35207683
pii: jpm12020195
doi: 10.3390/jpm12020195
pmc: PMC8879850
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
N Engl J Med. 2012 Feb 23;366(8):707-14
pubmed: 22356324
N Engl J Med. 2010 Aug 26;363(9):809-19
pubmed: 20818844
Lancet Oncol. 2015 Oct;16(13):1324-34
pubmed: 26342236
Ecancermedicalscience. 2019 Apr 03;13:920
pubmed: 31281417
JCO Precis Oncol. 2018 Aug 16;2:
pubmed: 32913998
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Oncotarget. 2018 Feb 2;9(15):12316-12322
pubmed: 29552312
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
N Engl J Med. 2006 Feb 23;354(8):809-20
pubmed: 16495393
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
Gastric Cancer. 2015 Jul;18(3):476-84
pubmed: 25038874
JCO Precis Oncol. 2018 Nov;2:1-11
pubmed: 35135160
Cancer Discov. 2017 Jun;7(6):586-595
pubmed: 28365644
Oncotarget. 2018 Apr 17;9(29):20282-20293
pubmed: 29755651
J Clin Oncol. 2012 Feb 1;30(4):372-9
pubmed: 22203755
Nat Genet. 2010 Aug;42(8):715-21
pubmed: 20601955
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
N Engl J Med. 2005 Oct 20;353(16):1659-72
pubmed: 16236737
J Clin Oncol. 2020 Nov 20;38(33):3883-3894
pubmed: 33048619
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
JCO Precis Oncol. 2018 Nov;2:1-13
pubmed: 35135159
Clin Cancer Res. 2020 Dec 15;26(24):6453-6463
pubmed: 32820017
N Engl J Med. 2005 Oct 20;353(16):1673-84
pubmed: 16236738
Genet Med. 2019 Dec;21(12):2676-2680
pubmed: 31160752